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Protein phosphatasehate (IP3) receptor (IP3R) is a universal intracellular Ca
2+-release channel. It is
activated after cell stimulation and plays a crucial role in the initiation and propagation of the complex
spatio-temporal Ca2+ signals that control cellular processes as different as fertilization, cell division, cell
migration, differentiation, metabolism, muscle contraction, secretion, neuronal processing, and ultimately
cell death. To achieve these various functions, often in a single cell, exquisite control of the Ca2+ release is
needed. This review aims to highlight how protein kinases and protein phosphatases can interact with the
IP3R or with associated proteins and so provide a large potential for ﬁne tuning the Ca2+-release activity and
for creating efﬁcient Ca2+ signals in subcellular microdomains.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
It becomes increasingly clear that intracellular Ca2+ signals
controlling many vital cellular processes are conﬁned to subcellular
microdomains. The molecular architecture of such microdomains is a
matter of intense investigation but is as yet still poorly understood.
Phosphorylation/dephosphorylation of the inositol 1,4,5-trisphosphate
(IP3) receptor (IP3R) and/or of associated proteins seems however to
play a crucial role. The IP3R was found to be a substrate for a wide
variety of different protein kinases and phosphatases and there is a
very large number of in silico predicted consensus sites for
phosphorylation as well as for docking of kinases and/or of their
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a huge potential for regulatory ﬁne tuning of Ca2+ release and
signaling. Phosphorylation of the IP3R is involved in many Ca2+-
signaling pathways linked to important cellular functions ranging
from oocyte maturation to cell death. It is therefore our aim to present
a comprehensive state-of-the-art review on the topic, and to indicate a
number of issues that need further investigation.
2. The inositol 1,4,5-trisphosphate receptor
Cell activation by extracellular agonists as hormones, growth
factors and neurotransmitters often leads to phospholipase-C (PLC)
activation and subsequent intracellular IP3 production. IP3 diffuses
through the cytoplasm until it binds and activates its receptor. This
IP3R is an intracellular Ca2+-release channel predominantly located
on the endoplasmic reticulum (ER) and responsible for a controlled
release of Ca2+ ions in the cytoplasm, which is crucial for setting up
complex spatio-temporal Ca2+ signals [1,2].
The functional IP3R/Ca2+-release channel is a tetramer. The four
subunits have a similar general structure, but IP3R diversity is created
in higher organisms by (i) the presence of 3 genes (ITPR1, ITPR2 and
ITPR3) encoding for IP3R1, -2 and 3 resp., (ii) the occurrence of splicing
events, and (iii) the possible formation of homo- and heterotetramers
[3]. Each subunit consists of about 2700 a.a., and the functional Ca2+-
release channel therefore has amolecularmass of around 1.2MDa. The
linear sequence of the IP3R consists of three large regions, an N-
terminally located IP3-binding region of about 600 a.a., a large
modulatory and transducing region (about 1600 a.a.) and a small
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domains. More recently, it has been shown that the N-terminal IP3-
binding region is composed of a suppressor domain and an IP3-
binding core, while the C-terminal region is composed of a channel
region and a coupling region (Fig. 1) [4]. Most work has been
performed on the ubiquitously expressed IP3R1, but it is assumed
that the various isoforms have the same general structure. In spite
of their similarity, it is however clear that the various IP3R isoforms
can subtly differ in their properties. Their afﬁnity for IP3 displays a
rank-order IP3R2N IP3R1N IP3R3 [5,6], which seems predominantly
due to differences at the level of the suppressor domains [7].
Additionally, differences in sensitivity for regulatory factors as e.g.
Ca2+, ATP and redox status were observed [5,8-15].
Cryo-electron-microscopy analysis demonstrated that IP3R1, and
the other isoforms probably as well, has a quite open structure [16]
allowing easy access of regulatory proteins to various sites on the IP3R.
In addition, the IP3R structure undergoes major conformational
changes under inﬂuence of Ca2+ [17]. Hence, many proteins can
directly interact with the IP3R, some of them at least in a
conformation- or isoform-speciﬁc way [3,18,19].
The physiological relevance of the existence of multiple IP3R
isoforms is reﬂected in the fact that they are expressed differently and
at varying subcellular localizations in the different cell types and
organs [20] and that their expression pattern changes during cellular
differentiation and development as well as under patho(physio)
logical situations [3].
Not unexpectedly, the IP3R isoforms contain on their sequences
multiple phosphorylation consensus sites and many docking sites for
protein kinases and phosphatases. Today at least 12 different protein
kinases are known to directly phosphorylate the IP3R. This, combined
with the fact that some important regulatory proteins associated with
the IP3R (IRBIT, see part 3, and Bcl-2, see part 4) are themselvesFig. 1. The structure of the IP3R1/Ca2+-release channel showing the proteins and the sites in
domains are indicated at the bottom of the ﬁgure [4]. Splice sites (S1, S2 and S3) are indicate
shown with their identiﬁed interaction sites on IP3R1. The interaction of IRBIT (broad arrow
suppressor domain as well. The coupling of PKC via RACK1 has not yet been described and is
has not yet been determinedwith certainty are not shown. Identiﬁed phosphorylation sites a
pink (by ERK) and orange (by Fyn). For more details, please see text.regulated by phosphorylation and/or can bind protein kinases or
phosphatases, makes the understanding of the regulation of the IP3R
by phosphorylation/dephosphorylation even more complex and the
functional consequences of this regulation are still only partially
understood.
3. IRBIT, the IP3R-binding protein released by IP3, and its role in
regulating the phosphorylation status of IP3R
3.1. Structure of IRBIT
IRBIT, the IP3R-binding protein released by IP3, corresponds to the
S-adenosyl-L-homocysteine hydrolase (AHCY)-like protein AHCYL1
(also termed DCAL, dendritic cell-expressed AHCY-like protein) and is
composed of a speciﬁc N-terminal IRBIT domain and a C-terminal
AHCY domain [21,22].
The AHCY domain of IRBIT closely resembles AHCY but contains
critical mutations (V256 and V450 instead of T158 and H353 resp., see
Fig. 2) and does not demonstrate any form of adenosylhomocysteine-
hydrolase activity [23]. It contains a PDZ-ligand that mediates an IP3-
insensitive interaction with the IP3R [24]. In contrast herewith the
IRBIT domain enables binding to the IP3R in a way that can be
competed by IP3 and additionally contains a protein phosphatase
(PP) 1 docking site, several phosphorylation sites and a PEST motif
(a.a. 65 to 92) that targets the domain for proteolytic degradation
(Fig. 2).
IRBIT was discovered as a ubiquitous protein with its highest
expression levels in neuronal tissue and the possibility to interact with
and to inhibit IP3R1, -2 and -3 [21]. During early embryogenesis, its
expression is tightly regulated; its microinjection in zebraﬁsh
embryos results in a dorsalized phenotype that is similar to the
results of pharmacological inhibition of the IP3R [25,26].volved in its regulation by phosphorylation/dephosphorylation. The various functional
d. Docking proteins (black), protein kinases (green) and protein phosphatases (red) are
) with the IP3R stretches over the complete IP3-binding core, and may encompass the
therefore indicated by a dotted line. Proteins of which the interaction site with the IP3R1
re shown in yellow (phosphorylation by PKA/PKG), blue (by PKB), pale green (by CDK1),
Fig. 2. The modular structure of AHCY and IRBIT (AHCYL1). IRBIT contains a C-terminal AHCY domain that is preceded by the speciﬁc IRBIT domain. The AHCY domain of IRBIT
contains a conserved PDZ ligand (orange), but has no enzymatic AHCY activity due to mutations of T158 and H353 to two valine residues (V256 and V450, indicated by asterisks). In
contrast with AHCY, it also contains a coiled-coil region (CC, green). The IRBIT domain is composed of a PP1-binding site (PP1, red) followed by a PEST-motif (PEST, blue) that can be
cleaved and that contains several phosphorylation sites: phosphorylation of S68 (grey circle) by an unidentiﬁed Ca2+-activated kinase allows subsequent phosphorylation of S71 and
S74 by CK1 (purple circles), while the protein kinases involved in the phosphorylation of T82, S84 and S85 (grey circles) are also not yet identiﬁed.
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The interaction of IRBIT with the IP3R is dependent on phosphor-
ylation of the IRBIT domain and occurs directly, without the need for
adaptor proteins [24]. The critical phosphorylation sites reside within
the PEST motif, where phosphorylation of S68 allows for subsequent
phosphorylation of S71 and S74 by casein kinase (CK) 1 [27,28]. The
latter two phosphorylations are both necessary and sufﬁcient to
enable IRBIT to bind to and inhibit the IP3R [27]. The identity of the
protein kinase that in vivo phosphorylates S68 remains to be
elucidated but interestingly all ﬁve candidates that are predicted
from in silico analysis (protein kinase D, Ca2+/CaM-dependent
protein kinase II (CaMKII) and IV, AMP-activated protein kinase and
mitogen-activated protein kinase (MAP kinase)-activated protein
kinase 2) are Ca2+-activated protein kinases [27]. The functional
relevance of the three other phosphorylation sites (T82, S84 and S85
[29]) is not known, but they could either enhance the phosphoryla-
tion-dependent interaction of IRBIT with its targets, or alternatively,
be a way to target IRBIT to different interaction partners.
The IRBIT domain is inactivated by dephosphorylation. PP1 has
previously been shown in complex with the IP3R via both a direct
interaction with the C-terminal tail of the IP3R [30], and an indirect
interaction via the large scaffold protein AKAP9 [31] (Fig. 1). We
recently showed that PP1 also binds directly to the IRBIT domain,
whereby the so-called RVXFmotif, [R/K]-X0–1-[I/V]-{P}-F, functions as
the docking site ({P} indicates any a.a. except proline) [27]. PP1
speciﬁcally dephosphorylates S68, but neither S71 nor S74. Noteworthy,
the dephosphorylation of S68 is strictly dependent on the direct
interaction between PP1 and the IRBIT domain [27]. It also prevents
the subsequent CK1-mediated phosphorylation of S71 and S74, and
hence the activation of the IRBIT domain. Inversely, inactivation of the
PP1 docking site increases the interaction of IRBIT with the IP3R [27].
The protein phosphatase(s) that dephosphorylate(s) S71 and S74
remain(s) elusive. It is also still unknown whether IRBIT-bound PP1
can affect the phosphorylation state of the IP3R.
The importance of the phosphorylation sites on the IRBIT domain
is underscored by the fact that IRBIT can in vivo be cleaved inside the
PEST domain, between the two CK1-dependent phosphorylation sites
(Fig. 2) [24,27]. This proteolytic cleavage represents an irreversible
way to inactivate the IRBIT domain, as neither IRBIT[1-73] nor IRBIT
[74-530] can bind to the IP3R [24]. Inactivation of IRBIT by proteolytic
cleavage and subsequent removal of the endogenous attenuation of
IP3-induced Ca2+ release (IICR) could therefore play a role in death-
signaling pathways [32].
3.3. Phosphorylated IRBIT inhibits the IP3R
When IRBIT is phosphorylated on S71 and S74, it can bind to the
IP3R [27]. Both IRBIT and IP3 bind to largely overlapping sites in theN-terminal region of the IP3R [24,28]. Their binding sites are however
not completely identical: mutation of R265 or T267 in the IP3R disables
the binding of IP3, but not of IRBIT [28]. Additionally, the suppressor
domain of the IP3R may be involved in the binding of IRBIT [24]
(Fig.1). Binding experiments demonstrated that phosphorylated IRBIT,
puriﬁed from Sf9 cells, has a ∼10-fold lower afﬁnity for the IP3R than
IP3 (IC50 ∼250 nM versus ∼26 nM) [24] which is however still
signiﬁcantly higher than the afﬁnity of other regulatory proteins
interacting with the IP3R as e.g. calmodulin (CaM; IC50 ∼2 μM [33,34]).
Though both IRBIT and IP3 interact with the IP3-binding core, the
former is unable to activate the IP3R channel [28]. Moreover, binding
of phosphorylated IRBIT competes with the IP3 needed for activating
the IP3R and for subsequent IICR [27]. This explains why phosphory-
lated IRBIT reduces IICR in permeabilized ﬁbroblasts and why this
effect can be overcome at high IP3 concentrations [24]. Similar results
were also observed in mouse cerebellar microsomes but overexpres-
sion of IRBIT appeared not to affect IICR in intact HeLa cells [28]. This
could be due to high endogenous levels of IRBIT and/or of its close
homologue AHCYL2. Inversely, silencing of IRBIT increased the
number of HeLa cells that responded to low levels of IP3 [28].
Overall, the functional in vivo role of IRBIT on the IP3R remains
puzzling and the observed effects are disappointingly small. This
could point to an additional cellular regulatory mechanism that
controls its activity. In this respect, it should be noted that pH could be
an important regulator of the interaction of the IRBIT domain with its
targets. We observed that an increase in pH decreases IRBIT binding to
the IP3R, while it increases the binding of IP3 [24]. Competition
between IRBIT and IP3 is therefore extremely dependent on intracel-
lular pH. Hence, it is possible that in vivo effects of IRBIT on the IP3R
can only be clearly observed in conditions of a (locally) decreased
intracellular pH. As IRBIT also targets Na+/HCO3- cotransporters [35] it
might constitute a link between intracellular pH regulation and Ca2+
signaling [22].
4. The anti-apoptotic Bcl-2 protein and its role in regulating the
phosphorylation status of IP3R
4.1. Structure and function of Bcl-2
Bcl-2 (B-cell lymphoma-2) is the prototype of a large family of pro-
apoptotic and anti-apoptotic proteins, characterized by one or more
speciﬁc domains, called Bcl-2 homology (BH) domains. Bcl-2 contains
four BH domains and appears embedded in the ER, nuclear envelope
and outer mitochondrial membrane via its hydrophobic C-terminal
tail [36]. Bcl-2 as well as other anti-apoptotic members of the Bcl-2
family, such as Bcl-Xl, can inhibit the multidomain pro-apoptotic
Bcl-2-family members Bax and Bak that lack the BH4 domain.
Activated Bax and Bak normally translocate to the mitochondria and
oligomerize, thereby leading to mitochondrial outer-membrane
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blebbing and removal. In addition, the hydrophobic groove formed
by BH domains 1–3 in as well the anti-apoptotic Bcl-2/Bcl-Xl as the
pro-apoptotic Bax/Bak can bind the amphipatic BH3 domain of the
so-called BH3-only pro-apoptotic proteins [36].
Besides this role at the level of the mitochondrial outer membrane,
many Bcl-2-family members seem to play a crucial role in controlling
the Ca2+ content of the ER and/or the Ca2+ release from it [37].
Although it is still not clear how regulation of intracellular Ca2+
homeostasis by the anti-apoptotic Bcl-2-family members is exactly
achieved, it is clear that IP3Rs hereby play a central role [38]. Recent
evidence demonstrated a binding site for Bcl-2 in the regulatory
region of the IP3R (Fig. 1) [39], while previous evidence indicated that
the related protein Bcl-Xl would bind in the C-terminal region [40].
Both Bcl-2 and Bcl-Xl seem to be able to interact with all three IP3R
isoforms [40,41], though isoform-speciﬁc effects have been described,
at least for Bcl-Xl [42]. The exact relation between the various IP3R
isoforms, Bcl-2/Bcl-Xl and their proposed binding sites remains
however to be further investigated. Interestingly, the anti-apoptotic
Bcl-2-family members display a dual role on Ca2+ signaling. At low
levels of cellular activation Bcl-2 and Bcl-Xl seem in lymphocytes so
to enhance pro-survival Ca2+ oscillations, thereby stimulating depho-
sphorylation of the nuclear factor of activated T cells (NFAT) and
mitochondrial bioenergetics, whereas they would inhibit pro-apopto-
tic sustained Ca2+ elevations, thereby preventing mitochondrial
outer-membrane permeabilization [40,43]. For more detailed infor-
mation on the action of Bcl-2 and Bcl-Xl on the IP3R, the interested
reader is referred to very recent reviews on the topic [44–46].
4.2. Regulation of the phosphorylation status of Bcl-2 and IP3R1 by Bcl-2
Bcl-2's activity has been shown to be dependent on its phosphor-
ylation state. In cells, Bcl-2 phosphorylation is induced in response to
diverse stimuli including chemotherapeutic taxanes, survival factor or
protein kinase C (PKC) [47]. In addition, it has been shown that Bcl-2 is
phosphorylated in a cyclin-dependent kinase (CDK) 1-dependent
manner in hypericin-photosensitized HeLa cells [48]. Phosphorylation
of Bcl-2 induces cell-cycle arrest in G2/M and leads to apoptotic
removal. Phosphorylation occurs in the unstructured loop region
between BH4 and BH3 and seems generally related to inactivation of
Bcl-2, since deletion of this loop or mutation of these phosphorylated
sites enhances the anti-apoptotic properties of Bcl-2 [49–53]. In
cycling Jurkat cells, Bcl-2 is phosphorylated by Jun N-terminal kinases
(JNK) during the G2/M cell cycle at T69, S70 and S87 [54]. Mutation in
Bcl-2 of these 3 amino acids to alanine (Bcl-2AAA) enhanced protection
against Ca2+-dependent death stimuli, such as arachidonic acid and
H2O2. In addition, overexpression of Bcl-2AAA in mouse embryonic
ﬁbroblasts was more potent in reducing the ER Ca2+ levels and
inhibiting mitochondrial Ca2+ uptake than overexpression of wild-
type Bcl-2. This indicates that phosphorylation of Bcl-2 can inactivate
its anti-apoptotic action and reverse its effects on ER Ca2+ dynamics.
This was recently conﬁrmed in epithelial cells, where JNK1 activation
occurs through Gα12, leading to Bcl-2 phosphorylation, degradation
and ultimately apoptosis [55]. Dephosphorylation of Bcl-2 is mediated
by different phosphatases, including PP1, PP2A and calcineurin (also
named PP2B) with which Bcl-2 seems to be able to directly interact.
Calcineurin interacts with the BH4 domain of Bcl-2 in various cell
types [56,57]. Subsequently, a Ca2+- and CaM-dependent interaction
of calcineurin was demonstrated with both Bcl-2 and IP3R1 in various
regions of the brain [58]. Moreover, as Bcl-2 seems to be required for
the calcineurin-IP3R1 interaction, it was proposed that Bcl-2 acts as a
docking protein for calcineurin on IP3R1 [59,60]. Calcineurin could
then dephosphorylate both Bcl-2 and IP3R1 and so contribute to Bcl-
2's anti-apoptotic functions [59].
A Bcl-2-dependent interaction of calcineurin with the IP3R may
help resolve the long standing problem how calcineurin targets theIP3R. Indeed, the original claim that calcineurin regulates IICR after
being targeted to the IP3R1 by FK506-binding protein (FKBP) 12
[61,62] is in contradictionwith subsequent results obtained by various
other groups [63-67]. Potential explanations for the effects of
calcineurin on IICR have already been presented elsewhere [68].
Efﬁcient dephosphorylation of the IP3R by calcineurin might however
also occur if the latter is targeted to the IP3R by another docking
protein as e.g. Bcl-2.
Bcl-2 has also been shown to directly interact with PP1 through a
RVXF motif present in the BH1 domain of Bcl-2 (a.a. 146–150) [69].
This study provided evidence that Bcl-2 can bind through PP1 to IP3Rs,
since siRNA-mediated knockdown of PP1 reduced the interaction
between Bcl-2 and IP3R1. Moreover, the authors suggested that IP3R1
and Bcl-2 competed for PP1 and that titrating Bcl-2 away by Bad
overexpression may increase the availability of PP1 for IP3R1 and may
induce increased IICR and apoptosis. This mechanism allows for an
indirect effect of Bcl-2 on IICR but would however imply that
dephosphorylation of IP3Rs activates the channel, whereas IP3R
channels are in most cases activated by phosphorylation (see part 5
and following). This interesting possibility for additional regulation
should therefore be further investigated.
Recently, Bcl-2 was shown to also co-immunoprecipitate with
PP2A from ER membranes [70]. Dephosphorylation of Bcl-2 appar-
ently regulates Bcl-2 levels in a dynamic way: inhibition of PP2A led to
degradation of phosphorylated Bcl-2 and a decrease in total Bcl-2
levels, whereas an increase in PP2A levels caused stabilization of
endogenous Bcl-2 levels. Hence, PP2A-mediated dephosphorylation
can protect Bcl-2 from proteasome-dependent degradation and
therefore modulate cellular sensitivity towards ER-stress stimuli.
Finally, another study demonstrated that in the absence of Bax/Bak
(i) Bcl-2 binding to IP3R1 was strongly enhanced, and (ii) IP3R1 was
hyperphosphorylated [71]. At least part of the hyperphosphorylation
was due to phosphorylation of S1755, a site that can be used by either
protein kinase A (PKA) or protein kinase G (PKG) (see parts 5 and
6). At the functional level, this hyperphosphorylation correlated
with an increased rate of Ca2+ leak from the ER and a lower steady-
state [Ca2+]ER. This effect could be abolished by siRNA-mediated
silencing of either Bcl-2 or IP3R1, but not of IP3R3, indicating a
speciﬁc effect of Bcl-2 on IP3R1 [71].
Taken together these results suggest that the ratio of pro- and anti-
apoptotic Bcl-2-family members speciﬁcally determines the phos-
phorylation status of IP3R1. Although Bcl-2 can bind different types of
phosphatases, no conclusive mechanism can be proposed to explain
how this effect is mediated.
5. Regulation of the IP3R by protein kinase A
The concept that the IP3R can be regulated by PKA is extremely
appealing, as it provides a possibility for cross-talk between the two
main intracellular messengers, cAMP and Ca2+. Differences in the
levels of bothmessengers and in the intracellular densities of IP3Rs and
PKA could in this way allow for the initiation of speciﬁc Ca2+ signals
[72]. A speciﬁc example of such a regulation can be found in the brain
where the distribution and subcellular localization of phosphorylated
versus unphosphorylated IP3R1 vary markedly between brain regions
and depend on the physiological condition [73].
In line with this, PKA-mediated phosphorylation of IP3R1 appears
very robust. In fact, this phosphorylation event was already demon-
strated in cerebellum before the identiﬁcation of the phosphoprotein
as the IP3R [74-78]. In spite of this early detection, the exact functional
consequence of this phosphorylation remained for a long time
controversial. This controversy may be due to the fact that multiple
proteins directly or indirectly related to Ca2+ handlingmay also be the
target of phosphorylation by PKA. Alternatively, it may be due to the
fact that PKA-mediated phosphorylation itself is under regulatory
control. Such regulation may involve a preliminary phosphorylation
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appeared that the PKA-mediated inhibition of IICR only occurred
when IP3R1 was already phosphorylated by a yet unidentiﬁed
endogenous kinase [79]. Also regulation by ATP can be involved: the
peripheral IP3R1 isoform contains an additional nucleotide-binding
fold which seems to be unrelated to the ATP-dependent regulation of
the IP3R1 [80]. A mutation inside this fold (G1690A) however
precluded both the PKA-dependent phosphorylation of the receptor
and the subsequent potentiation of the IICR, suggesting a relation
between ATP binding and PKA-mediated sensitization of IP3R1.
PKA can phosphorylate two distinct sites on IP3R1 (S1588 and S1755,
see Fig. 1), both located in the regulatory region of the receptor and
separated by the S2 splice domain that is typically present in the adult
neuronal IP3R1 isoform [81]. In this isoform, the primary phosphor-
ylation site appears to be S1755. Splicing out of the insert affects the
phosphorylation process as the peripheral IP3R isoform appears about
ﬁve-fold more sensitive to PKA and is predominantly phosphorylated
at S1588 [82]. Targeting of PKA to both the neuronal and the peripheral
IP3R1 isoforms is mediated by the anchor protein AKAP9 (also named
yotiao) which interacts with a non-canonical leucine/isoleucine
zipper domain in the regulatory region of the IP3R1 (a.a. 1251–
1287, see Fig. 1) [31]. In chromafﬁn cells, the epidermal growth
factor receptor forms also part of the signaling complex, which
would be recruited after stimulation by bradykinin [83].
Although it was originally proposed that the IP3R was inhibited
after phosphorylation by PKA, model systems relying on immunopur-
iﬁed IP3R1 reconstituted in lipid vesicles [84] or single-channel
measurements in planar lipid bilayers [30] conclusively demonstrated
that PKA-mediated phosphorylation leads to a direct increase in the
sensitivity of IP3R1 towards IP3 without shifting its Ca2+ sensitivity.
Similar conclusions were drawn from analysis of Ca2+ signals in
IP3R DT-40 triple knock-out cells heterologously expressing IP3R1.
Mutation analysis of the neuronal and peripheral isoforms of IP3R1
indicated that phosphorylation of S1755 was crucial for increasing the
sensitivity of the neuronal isoformwhile both S1589 and S1755 had to be
phosphorylated to increase the sensitivity of the peripheral isoform
[85,86]. Phosphomimetic mutations in IP3Rs expressed in DT-40 cells
moreover indicate that PKA-mediated phosphorylation lowers the
threshold for Ca2+ oscillations, but does not affect their amplitude or
frequency [86]. A detailed electrophysiological analysis of the IP3R1
(peripheral isoform) in the same cell type indicated that the main
effect of PKA-mediated phosphorylation was to decrease the prob-
ability of the IP3R1 to reside in the closed state and so to increase the
likelihood of extending burst activity and thus Ca2+ release [87].
PKA-mediated phosphorylation and activation of IP3R1 is counter-
acted by PP1α [30]. Interestingly, the C-terminus of IP3R1 can bind
PP1α but not the β and γ isoforms and none of the PP1 isoforms
shows signiﬁcant binding to the C-termini of IP3R2 and -3, indicating a
very speciﬁc interaction [30]. As IP3R1 can also bind PP1 indirectly via
AKAP9 [31] or via associated proteins as IRBIT or Bcl-2 (see parts 3 and
4 resp., Fig. 1) it remains to be clariﬁed which PP1-binding site(s) is
(are) functional in vivo.
PKA-mediated phosphorylation cannot only affect IICR in a direct
way, but might also indirectly affect the IP3R by modulating its
interaction with other regulatory factors. At least for the peripheral
IP3R1 isoform, PKA-mediated phosphorylation attenuates CaM bind-
ing to it [88]. This effect was related to the phosphorylation of the
upstream PKA site and counteracted by PP1 [89]. The decreased
binding of CaMmay help to explain the increase in IICR observed after
PKA-mediated phosphorylation. In addition, it might explain why in
some other studies no PKA-mediated increase in IICR was observed, as
depending of the cell type and the technique used, different levels of
CaM may be present.
The potentiating effect of PKA on IICR was also observed in studies
on tissues or cell types in which IP3R1 is not the main isoform (e.g. in
hepatocytes), though the presence of homomeric or heterotetramericIP3R1 in those cells does not allow to make conclusions on the effects
of PKA on the other isoforms. As the above-mentioned residues of
IP3R1 phosphorylated by PKA are not conserved between the
isoforms, differences in action of PKA can be expected. It also appears
that although the leucine/isoleucine zipper region is conserved in
IP3R2 and -3, AKAP9 failed to bind to these isoforms [31].
Comparison of the three immunoprecipitated isoforms already
indicated that phosphorylation was much less effective for IP3R2 and
-3 than for IP3R1 [90]. Effects of PKA-mediated phosphorylation on
speciﬁcally the IP3R2 and -3 isoformswere therefore only investigated
in a limited number of studies.
For IP3R2 in parotid cells, evidence was presented for its PKA-
mediated phosphorylation, which correlated with an increased Ca2+-
release activity [91]. A detailed study in the pancreatic AR4-2J cell line
that expresses for 86% IP3R2 came to the same conclusions [92]
suggesting that IP3R2 is phosphorylated and activated by PKA.
For IP3R3, like for IP3R1, contradictory results were published. At
the one hand a PKA-mediated inhibition of IICR was demonstrated in
parotid and pancreatic acinar cells [93–95]. In RINm5F insulinoma
cells expressing high levels of IP3R3 however a PKA-mediated
activation of IICR was observed by different groups [90,96,97]. Three
PKA-dependent phosphorylation sites were identiﬁed in IP3R3, i.e.
S916, S934, and S1832, whereby S934 was the preferential phosphoryla-
tion site [98]. The relation between phosphorylation of these serine
residues and changes in IP3R3 activity is however not clear. In DT-40
cells PKA inhibited IICR after either B-cell-receptor (BCR) stimulation
or activation of the protease receptor PAR2, irrespectively whether
wild-type IP3R3 or IP3R3 mutated at one or several of the above-
mentioned serine residues were expressed [99]. This observation
indicates that the phosphorylated serine residues may not directly
affect IP3R3-channel function but may contribute to the scaffolding
role of IP3Rs and/or that another PKA substrate is involved in the
inhibitory effect on IICR, and this in a cell-type dependent way.
6. Regulation of the IP3R by protein kinase G
PKG has a high homology to PKA but a muchmore restricted tissue
distribution, with highest level in the lung, cerebellum and smooth
muscle [100]. In the latter two tissues it was demonstrated that IP3R1
could be phosphorylated by PKG [101-103]. The phosphorylation
event is however less pronounced than with PKA and was initially
missed. PKG phosphorylated the same sites on IP3R1 as PKA (Fig. 1)
[85,101,104], though the site preferentially used seems not only to be
dependent on the splice isoform but also on the phosphorylation
conditions [105].
In smooth muscle, IP3R1 and PKG are found in a multiprotein
complex also containing a protein called IRAG for “IP3R-associated
cGMP kinase substrate” [106]. The latter is a relatively large protein
(125 kDa) that links IP3R1 to speciﬁcally the Iβ isoform of PKG. The
formation of this complex does not depend on the phosphorylation of
IRAG but when itself phosphorylated on S696, IRAG leads to
diminished IICR [107].
Similarly to PKA, both stimulatory [108] and inhibitory actions
[109,110] on IICRwere described. Thismight be related to the presence
or absence of IRAG [107]. Another complication for the interpretation
of the results is that, at least under some conditions, cAMP can lead to
PKG-mediated phosphorylation [103,104], while cGMP can also
induce an IP3R-independent Ca2+ release [111].
Concerning the other IP3R isoforms, much less is known. A modest
phosphorylation by PKG was observed for IP3R3, at the same site
(S934) that is predominantly used by PKA for this isoform [98].
7. Regulation of the IP3R by Ca2+/CaM-dependent protein kinase II
CaMKII belongs to a different type of kinase, and exists as an
assembly of 8–12monomers which is found in most tissues, though in
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sensitive to Ca2+ and CaM and has the ability to decode Ca2+
oscillations [112], regulation of IICR by CaMKII would constitute an
obvious feedback mechanism whereby Ca2+ would regulate its own
release.
Ca2+ has since long been recognized as a basic feedback regulator
of the IP3R and of the subsequent IICR (reviewed in [3,113-116]). The
regulation by Ca2+ is biphasic, with activation in the sub-micromolar
range and an inhibition at higher Ca2+ concentrations. Ca2+ activation
has been consistently found in different cell types as well as in in vitro
reconstitution systems, e.g. in bilayer experiments, suggesting that the
determinants of the activation are probably intrinsic features of the
IP3R. On the other hand, the inhibition is highly variable, depending on
IP3R subtype, cell type and experimental conditions [3]. This can be
interpreted as a result of different types of Ca2+-dependent regulation
including regulation of the IP3R via Ca2+/CaM and via Ca2+/CaM-
dependent phosphorylation [117]. As IRBIT is also a substrate for
CaMKII (see part 3) an additional mechanism involving CaMKII would
be that the phosphorylation of IRBIT forms part of the negative
feedback mechanism.
In many studies Ca2+ was found to mediate its effects via Ca2+-
sensor proteins and particularly via CaM and the broad family of CaM-
like Ca2+ sensors. CaM so interacts with all three IP3R isoforms [115].
The existence of multiple sites for CaM interaction on IP3R1 has been
documented [34,88,118–120]. Inhibitory effects of CaM on IICR have
been demonstrated by various groups and under various conditions
121–124]. More recently evidencewas presented that additionally one
of the CaM-binding sites might lead to IP3R stimulation [120], though
this latter mechanism is the matter of some debate [125]. In addition,
CaM can act through activation of the multifunctional CaMKII and
phosphorylation of IP3R1 by CaMKII was already reported early on
[78,126].
Up to now, precise identiﬁcation and location of CaMKII phosphor-
ylation sites on the IP3R have not been reported. Depending on the
stringency of the deﬁnition of the consensus motif multiple potential
sites are possible. The R-X-X-[S/T]motif [127] is found between 11 and
19 times, depending on the isoform [128]. Screening for a consensus
site L-X-R-X-X-[S/T] shared by several types of CaM-dependent
kinases [129] yields however only 1 to 3 sites on each isoform, but
they are not conserved in an isoform- or species-dependent way.
The role of CaMKII-mediated phosphorylation has been implicated
from functional observations using inhibitors such as KN-62 [130].
CaMKII was proposed to be involved in the control of the Ca2+-
dependent regulation of IICR [131–133] and in the occurrence of Ca2+
oscillations [134–136]. In the latter study the inhibitory effect of
CaMKII on IICR could be discriminated from CaMKII effects on IP3
3-kinase [137,138]. The effects of CaMKII were also demonstrated
using more speciﬁc CaMKII peptide inhibitors [136], which is
important as e.g. the CaMKII inhibitor KN-93 was found to directly
inhibit IP3R1 by binding to a CaM-binding site [139].
Co-distribution of CaMKII and IP3R3 was reported in tissues of the
gastrointestinal tract [140], but the most extensive information
concerning regulation by CaMKII was obtained for IP3R2, the
predominant IP3R isoform in cardiac ventricular myocytes [141].
CaMKIIδB was found to co-localize with IP3R2 in the nuclear envelope
and to interact with and phosphorylate IP3R2 within the 1-1078 N-
terminal region [141]. The phosphorylation signiﬁcantly decreased the
open probability of IP3R2 in lipid bilayers and it was suggested that
IP3R2 and CaMKIIδB may represent a signaling complex with negative
feedback on IP3R2 function in the myocyte nuclear envelope [141,142].
Such a negative feedback resulting from inhibition of IP3R activity by
CaMKII may be the cause of the effects of CaMKII on Ca2+ oscillations
[134], neurotransmitter release [143] and on transcription-factor
translocation between cytoplasm and nucleus [144]. It is well
established that neuronal activity regulates gene expression via
intracellular Ca2+ and downstream Ca2+-sensitive enzymes [145]. Inthis respect it is relevant that IP3R expression as well as splice
selection in cerebellum granule neurons was found to be modulated
by Ca2+/CaM-dependent kinases (particularly CaMKIV), thus pro-
moting the expression of a distinct splice isoform in these cells [146].
8. Regulation of the IP3R by protein kinase C (PKC)
PKC belongs together with PKA/PKG and protein kinase B (PKB) to
the so-called ABC kinases which have a conserved kinase core under
allosterical control of a regulatory moiety. Based on the properties of
the latter, the PKCs are usually further divided into three subfamilies,
the conventional, the novel and the atypical PKCs [147]. The
conventional PKCs (α, β and γ) depend for their activity on Ca2+
and diacylglycerol (DAG), which both increase after cell stimulation
and subsequent PLC activation. Regulation of the IP3R by PKC would
therefore constitute a potential feedbackmechanism. In that respect it
is interesting to note that both the G-protein coupled receptors and
PLC itself are also under feedback control of PKC [148]. It should be
noted that PKC activation leads to changes in the subcellular
localization of IP3Rs in various cell types, which may reﬂect on their
function [149,150]. It is however not known whether the IP3R itself is
phosphorylated during this process. Finally, it is important to realize
that the various PKC isoforms can affect Ca2+ signaling differently
[151,152].
Puriﬁed and reconstituted neuronal IP3R1 can be phosphorylated
in vitro by brain PKC [126]. The phosphorylation site is different from
the PKA phosphorylation sites but is still unidentiﬁed. The general
consensus motif for PKC is [R/K]-X-[S/T]-X-[R/K] [153]. This motif can
be found between 3 and 6 times, depending on the IP3R isoform [128].
Evidence suggests that the phosphorylation of IP3R1 by PKC is
speciﬁcally counteracted by the phosphatase calcineurin [61]. Calci-
neurin potentially interacts with the IP3R1 through another protein,
but as stated above in part 4, the identity of the docking protein, if any,
is still unknown. In addition, recent results indicate that the potential
docking protein FKBP12 not only could affect IICR via calcineurin but
also by inhibition of the mammalian target of rapamycin (mTOR), an
S/T protein kinase related to the phosphoinositol kinases that can
potentiate IICR in smooth muscle [67]. It is however not known
whether mTOR acts directly on the IP3R or whether the effect is
mediated by another kinase as PKC or CDK.
Interaction of PKC with its substrates can either be direct or be
mediated by a scaffold protein, the receptor for activated C kinase
(RACK) 1. It is therefore possible that PKC itself forms part of a
multiprotein complex with the IP3R [18]. Interestingly, RACK1
interacts with the IP3R (Fig. 1), but no evidence was yet presented
that it played a role in the anchoring of PKC to the IP3R [154].
Functional effects of PKC-mediated phosphorylation of the IP3R
were ﬁrst demonstrated in isolated rat liver nuclei where Ca2+ release
through the IP3R was augmented after PKC activation [155]. When
calcineurin is inhibited or when the interaction of calcineurin with
IP3R1 is disturbed by e.g. FK506 [61,156,157], PKC-mediated phos-
phorylation of IP3R1 is enhanced in vivo as is IICR, suggesting that
phosphorylation of the IP3R by PKC leads to increased Ca2+ release.
Furthermore, PKC-mediated phosphorylation of IP3R1 can in vitro
be regulated by PKA, Ca2+ and CaM [158]. As both Ca2+ and CaM
inhibit the PKC-mediated phosphorylation of IP3R1, it is possible that
this process may contribute to the negative slope of the Ca2+-
dependent bell-shaped regulation of IP3Rs by Ca2+ (see part 7).
The group of Guillemette recently investigated the role of PKC-
mediated phosphorylation of IP3R2 [159] and -3 [160]. It seems that
when IP3R2 or -3 is phosphorylated by PKC, IICR is decreased in cells
expressing almost exclusively those isoforms. In this case PKC is
functioning as a negative regulator of intracellular Ca2+ release. This
difference in the effect of PKC phosphorylation on IICR between IP3R1
and the other isoforms is not unexpected as they possess different
potential phosphorylation sites [128,160] and it is still neither known
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mechanisms. At least under in vitro conditions, phosphorylation of
IP3R3 by PKC is unaffected by Ca2+ or CaM [158].
9. Regulation of the IP3R by protein kinase B
PKB (also called Akt) also belongs to the family of the ABC kinases.
Three highly homologous isoforms (α, β, γ) are expressed in
mammalian cells, all playing crucial functions in the processes of cell
proliferation and cell survival [161,162]. As it is known that high levels
of Ca2+ release can promote apoptosis [38,44,163], it is conceivable
that PKB could have pro-survival effects by suppressing IICR.
All three IP3R isoforms have an R-X-R-X-X-[S/T] consensus site for
PKB, which is located in their C-terminal tail (for IP3R1 this is S2681, see
Fig. 1). PKB phosphorylates the IP3R in vitro and in vivo at this site, but
a difference in IP3R properties could at ﬁrst not be shown, although in
cells expressing a non-phosphorylatable IP3R1 mutant caspase
activation was stimulated after treatment with staurosporine [164].
This result is provocative and strongly suggests that PKB regulates in
some way either Ca2+ release itself, e.g. by affecting IP3-independent
Ca2+ release through the channel portion of the IP3R [165], or else
interferes with the ER to mitochondria Ca2+-transfer process [164].
Interestingly, a subsequent study indicated that PKB interacted
between a.a. 2431 and 2749 of the IP3R1 (Fig. 1), conﬁrmed the
phosphorylation by PKB of S2681, but also demonstrated an inhibitory
effect on IICR occurring simultaneously with a reduced sensitivity to
apoptosis in various cell types [166]. The latter results are also in line
with a more recent study investigating Ca2+ homeostasis in HeLa cells
[167]. The reasons for the discrepancy in the effect on IICR between
the ﬁrst study and the latter two is not clear, but might be related to
the cell types used: the low endogenous PKB activity in chicken
DT-40 B-lymphocytes [166] may have obscured the effects.
10. Regulation of the IP3R by cell cycle-dependent protein kinases
The cell cycle is a complex process exquisitely regulated by
successive phosphorylation and dephosphorylation and where var-
ious protein kinases play a role. Important kinases hereby are the
various CDKs, extracellular-signal regulated kinases (ERK) and polo-
like kinases (PLK) [168–170].
Awell-studied cellular system is the (mammalian) oocyte where it
was shown that the activity of all these kinases changes during the
processes of oocyte maturation and egg activation [171–173]. More-
over, in those oocytes the capacity of releasing Ca2+ through the IP3R
increases during maturation, reaching an optimal activity at the time
of fertilization [174]. After fertilization a single, large Ca2+ transient is
initiated, followed by Ca2+ oscillations that last several hours, and that
disappear at interphase in a pattern which might be related to the
changes in kinase activity [175–177]. Changes in IP3R activity do not
only occur in oocytes but also in somatic cells when progressing
through mitotic divisions [178]. It therefore was a legitimate question
to investigate whether the IP3R is under direct control of cell cycle-
dependent protein kinases.
CDK1 (also called cdc2 for cell division cycle 2) assembles with the
regulatory protein cyclin B to form the maturation-promoting factor,
which is important for the start of oocyte maturation. It phosphor-
ylates substrates at an [S/T]-P-X-[K/R] consensus motif [179]. The
IP3R1 contains two phosphorylation sites for CDK, S421 and T799, which
both can be phosphorylated in vitro and in vivo by CDK1/cyclin B
(Fig. 1) [180]. S421 is conserved in IP3R1 from Drosophila to human
but not in IP3R2 or -3; T799 on the other hand is conserved in both
IP3R1 and -3. Moreover, R391, R441, and R871, each located in an RXL
cyclin-binding motif, are essential for allowing the coupling of CDK1/
cyclin B to the IP3R1 (Fig. 1) [181]. Both cyclin A and B were also
shown to interact with IP3R3, but the binding sites were not yet
identiﬁed [182]. CDK1/cyclin B-mediated phosphorylation of IP3R1,especially at T799, resulted in a 3-fold increase in IP3-binding activity
and also in an increased IICR activity [180,181].
The MAP kinases ERK1 and ERK2 are cell cycle-dependent kinases
that phosphorylate an [S/T]-Pmotif, with P-X-[S/T]-P as optimal motif
[179]. In mouse IP3R1 there are 3 potential ERK1/2 phosphorylation
sites: S436, T945 and S1765. From those only S436 and T945 are conserved
between mammals and Xenopus and S436 is also conserved in
Drosophila. None of them however are conserved in IP3R2 or -3. In
addition, the docking motif for MAP kinases, a short sequence called
the D domain, is found in mouse IP3R1 (a.a. 2078–2087, see Fig. 1),
suggesting a role for IP3R1 downstream of ERK1/2 activation. In vitro,
mouse cerebellar ERK1/2 interacts with this D-domain and two of the
three potential sites on IP3R1 (S436 and S1765, see Fig. 1) are
phosphorylated by ERK2 [183]. In agreement with the fact that
those phosphorylation sites are not conserved between the various
IP3R isoforms, in vitro experiments on puriﬁed IP3R1 and -3
demonstrated that only the former could be phosphorylated by
ERK2 and suggested S436 to be the major phosphorylation site [184].
Also in agreement with the preceding, functional effects were yet
only demonstrated for ERK-mediated phosphorylation of S436. Inter-
estingly, this residue is located in the hinge (a.a. 435–437) between
the two parts of the IP3-binding core, the β-trefoil and the α domain
with the armadillo repeats [4]. This critical location can explain why
upon phosphorylation of S436 by ERK the binding of the suppressor
domain to the IP3-binding core is strengthened while IP3 binding is
decreased. A decreased IICR was hereby observed [183,185].
In oocytes, a cell model expressing predominantly IP3R1 [186], the
reactivity of IP3R1 with the mitotic protein monoclonal 2 (MPM2)
antibody recognizing a [pS/pT]-P epitope [187], correlated well with
ERK activity: theMPM2 phosphorylation of the IP3R1 increases during
oocyte maturation, is maximal at MII and decreases again after
fertilization [184]. Pharmacological inhibition of the upstream kinase
MEK by U0126 demonstrated that ERK was responsible for this MPM2
reactivity of IP3R1. When ERK activity was inhibited, Ca2+ oscillations
were also impaired, indicating a stimulatory effect of ERK on IICR,
which is different from the effects described in somatic cells [183,185].
However this stimulation by ERK might be indirect, e.g. by regulating
the relative subcellular localization of the IP3R1 to that of another
MPM2-generating kinase [184,188].
Moreover, at early stages of maturation the MPM2 reactivity of
IP3R1 was not abolished in the presence of U0126, suggesting that
another kinase is then phosphorylating the IP3R1 at anMPM2-reactive
epitope [188]. A possible candidate for this is PLK1 [189]. PLK1
phosphorylates proteins on the consensus sequence [E/D]-X-[S/T]-Φ-
X-[D/E] (Φ indicates any hydrophobic a.a.) [190]. There are in IP3R1
three serines or threonines located in such consensus sites: T1048, S1790
and T2656. The latter site is very well conserved, as well across species
as across the various isoforms. In contrast herewith T1048 and S1790 is
conserved from Xenopus to humans in IP3R1 but are not conserved in
IP3R2 and -3. Both IP3R1 and -3 are in vitro phosphorylated by PLK1
(unpublished data). More importantly, we demonstrated that PLK1 is
indeed the kinase responsible for the MPM2 reactivity of the IP3R1 in
mouse oocytes in vivo [188]. These results therefore strongly suggest
an important role for PLK1 in the regulation of IICR during oocyte
maturation. Its mechanism of action has however still to be resolved.
11. Regulation of the IP3R by Rho kinases
Binding of hyaluronan to the plasma-membrane protein CD44
promotes adhesion, proliferation and migration of endothelial cells
and these processes aremediated by monomeric GTPases as RhoA and
the subsequent activation of Rho kinase. Aortic endothelial cells
express the three IP3R isoforms but after hyaluronan binding, Rho
kinase-mediated phosphorylation was predominantly observed for
IP3R1, and only to a much lesser extent for IP3R2 and -3 [191].
Functionally an increased IP3 binding and an increased IICR were
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process however appears much more complicated and other path-
ways, including IP3 production, tyrosine kinases and interaction with
cytoskeletal proteins, may all contribute to the increased IICR.
12. Regulation of the IP3R by tyrosine kinases
The mammalian non-receptor tyrosine kinases are divided in 10
families, of which the largest is the Src family containing 8 members
[192]. At least 3 members of this family were described to
phosphorylate the IP3R, though it is not yet clear whether they all
act in a similar way.
The ﬁrst demonstration of phosphorylation of tyrosine residues of
the IP3R1 was obtained during T-cell activation [193]. Subsequent
experiments indicated that both Src and Fyn could in vitro
phosphorylate IP3R1 in brain and in T-lymphocytes [194]. Although
Fyn can probably phosphorylate more than one site on IP3R1, most of
the phosphorylation occurs at a single site, Y353, located in the β-
trefoil domain of the IP3-binding core, just downstream of the S1
splice site (Fig. 1) [195]. Moreover, it is this site that is speciﬁcally
phosphorylated after T-cell or B-cell stimulation, suggesting its
importance during these processes.
In T-lymphocytes, the interaction of the major histocompatibility
complex II loadedwith antigens with the T-cell receptor (TCR) leads to
a cascade of events. One of the early steps is the activation of several
non-receptor tyrosine kinases, leading to phosphorylation of the TCR
and activation of PLCγ1. At that moment a colocalization of IP3R1 and
activated TCR occurs [196]. This colocalization is in fact the reﬂection
of the formation of a larger macromolecular complex, as both Fyn
[194] and the scaffold protein LAT, both positive regulators of PLCγ1
[197], associate with the IP3R. Moreover, this clustering of the IP3R1 at
the side of TCR activation does not represent a general ER
reorganization, but a speciﬁc movement of IP3R1 [197]. Whether
there is any mechanistic relation between IP3R1 phosphorylation and
its redistribution is here again not yet known.
Functional experiments conﬁrm that Fyn-mediated phosphoryla-
tion of IP3R1 is important for T-cell activation. It leads to a 5-fold
increase in afﬁnity for IP3 [195,197] as well as to a sensitization of the
channel, even at concentrations of Ca2+ that are normally inhibitory
[194,197], which means that IP3R1 continues to release Ca2+ during
the phase of declining [IP3] and of sustained [Ca2+] elevation
associated with T-cell activation [195], allowing for continuous
store-operated Ca2+ entry and NFAT activation.
In contrast with the more widely expressed Src and Fyn, Lyn
belongs to a subfamily of Src that is expressed only in hematopoietic
cells, and a deﬁciency in Lyn is characterized by a reduction in B-cell
development and activity [192]. After crosslinking of the BCR by
antigen binding, a phosphorylation cascade is initiated which begins
with Lyn phosphorylating the BCR as well as other proteins. In the
cascade PLCγ2 is activated and IP3 is produced. Proteins that are
phosphorylated by Lyn appear to be IP3R1 and -2 [198]. Their
phosphorylation site is not yet identiﬁed, but the interaction of Lyn
with the IP3R and the subsequent phosphorylation of the latter is
mediated by a scaffold protein named BANK, which is itself also
phosphorylated in the process. BANK can interact through its N-
terminal domain (a.a. 1–154) to the IP3R, while a more C-terminally
located part (a.a. 367–653) is involved in its interaction with Lyn.
Physiologically, BANK does not lead to an upregulation of PLCγ2
activity, but, probably by mediating IP3R phosphorylation by Lyn,
enhances Ca2+ signaling in a process reminiscent, but not identical, to
the relation between Fyn, LAT and IP3R in T cells.
13. Conclusion and perspectives
The importance of phosphorylation/dephosphorylation in the
regulation of IICR is very much dependent on the cellular context.Many different kinases can phosphorylate the IP3R, but IP3R isoform-
speciﬁc differences occur with respect to the presence of phosphor-
ylation sites as well as of docking sites for the different protein kinases
and phosphatases. Moreover, it became clear that the formation of
multiprotein complexes, whereby regulatory proteins associating
with the IP3R are themselves both substrates for kinases and
phosphatases and scaffold proteins allowing the proximity of kinases
and phosphatases towards the IP3R, is important for the localized
regulation of Ca2+ signals.
Although most effort has been directed to identify the kinases
involved, it is also increasingly evident that protein phosphatases are
very much involved in such multiprotein complexes. To understand
the function of IICR in deﬁned cellular conditions and/or in subcellular
microdomains it will therefore be crucial to further determine which
scaffolding and docking proteins are coupling kinases and phospha-
tases to the different IP3R isoforms.
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